Monthly Archives: April 2016

Archive of posts published in the specified Month

Written on Apr, 27, 2016 by in

Scientists are the explorers of the great unknown. They thrive on the inherently mysterious nature of their work and utilize their knowledge and instincts to engage with, better understand and predict the world and universe around us. One of the most valuable tools available to scientists is the chance to learn from fellow researchers. With this in mind, Tempo will be publishing a number of interviews with some of today’s great minds in science! This will be the first of several we’ll conduct and publish over the next few months. Without further ado, let me introduce: Dr. Ellen Moran.

Ellen is an accomplished biomedical researcher, writer, and editor. In 2009, she earned a PhD in translational research, specifically in rheumatology. Her published papers focus mainly around immunology and biochemistry and include 8 internationally peer reviewed articles. She also works on a freelance basis in scientific writing and communications including writing and editing for the websites Bitesize Bio, Bitesized Immunology, and Things We Don’t Know. She has worked in the UK, Australia and Ireland and has traveled to numerous conferences both national and international. She is currently working as the Laboratory Manager for a number of different research groups at the Education and Research Center in St. Vincent’s University Hospital, Dublin, Ireland. (more…)

Continue Reading...
Written on Apr, 21, 2016 by in

A xenograft (or heterograft) is a piece of living tissue taken from a donor of one species and grafted into a recipient of different species. Cancer refers to a group of diseases characterized by uncontrolled division of abnormal cells in a part of the body. According to WHO’s (World Health Organization) site, cancer is one of the leading causes of morbidity (rate of illness) and mortality (rate of death) worldwide, with approximately 14 million new cases and 8.2 million cancer-related deaths in 2012. With the number of annual cases set to rise to 22 million within the next 2 decades, the search for new drugs is both vital and urgent.

According to the FDA, the rate of success for a medicinal compound entering phase I testing actually reaching the market is only 8%. These drugs would have shown signs of efficacy in in vitro and/or in animal models and yet the culmination of perhaps a decade of pre-screening and evaluation results in another failure to translate into success in human studies. While the reasons for this are complex, one major factor is the need for cancer models that better represent the native tumor microenvironment and thus respond to potential cancer drugs in a manner more representative of a human response.

In the search for the best cancer drug models, one type of model of particular note are patient-derived tumor xenograft (or PDTX) mice. Here, we’ll discuss the pros and cons of PDTX mice as cancer models. (more…)

Continue Reading...
Written on Apr, 12, 2016 by in

Spinal Cord Injury/Disease SCI/D (or simply SCI) is defined as damage to any part of the spinal cord or nerves at the end of the spinal canal, the result of which is often permanent changes in the strength, sensation and other functions of the body from below the site of the injury. In 2013, WHO (World Health Organization) reported that as many as 500,000 people worldwide suffer from a spinal cord injury each year. In the US, 250,000 to 450,000 people live with SCI and there are 10,000-12,000 new cases annually. The causes are broad but around 70% of SCIs are caused by either vehicular injury or damage sustained by a fall and most of the rest are caused by violence (mainly gunshots violence) and sports-related injuries (mainly diving). Around 80% of SCI patients are men in their mid-teens to early thirties. (more…)

Continue Reading...